Assessing trends in breast care surveillance metrics after implementing surgeon-specific tracking and performance reporting in a large, integrated cancer network.


Journal

Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236

Informations de publication

Date de publication:
15 10 2023
Historique:
revised: 06 04 2023
received: 23 01 2023
accepted: 02 05 2023
medline: 22 9 2023
pubmed: 29 6 2023
entrez: 29 6 2023
Statut: ppublish

Résumé

There are few quality metrics and benchmarks specific to surgical oncology. Development of a surgeon-level performance metrics system based on peer comparisons is hypothesized to positively influence surgical decision-making. This study established a tracking and reporting system comprised of evidence and consensus-based metrics to assess breast care delivered by individual surgeons. Surgeons' performance is assessed by a surveillance tracking system of metrics pertaining to referrals and surgical elements. This retrospective analysis of prospectively collected breast care data reports on recurring 6-month and cumulative data from nine care locations from 2015 to 2021. Breast care was provided to 6659 patients by 41 surgeons. A total of 27 breast care metrics were evaluated over 7 years. Metrics with consistent, proficient results were retired after 18 months, including the rate of core biopsy, specimen orientation, and referrals to medical oncology, genetics, and fertility, among others. In clinically node-negative, hormone receptor-positive patients 70 years of age or older, the cumulative rate of sentinel lymph node (SLN) biopsy significantly decreased by 40% over 5.5 years (p < .001). The overall breast conservation rate for T0-T2 cancer increased 10% over 7 years. At the surgeon level, improvements were made in the median number of SLNs removed and in operative note documentation. Implementation of a surgeon-specific, peer comparison-based metric and tracking system has yielded substantive changes in breast care management. This process and governance structure can serve as a model for quantification of breast care at other institutions and for other disease sites.

Sections du résumé

BACKGROUND
There are few quality metrics and benchmarks specific to surgical oncology. Development of a surgeon-level performance metrics system based on peer comparisons is hypothesized to positively influence surgical decision-making. This study established a tracking and reporting system comprised of evidence and consensus-based metrics to assess breast care delivered by individual surgeons.
METHODS
Surgeons' performance is assessed by a surveillance tracking system of metrics pertaining to referrals and surgical elements. This retrospective analysis of prospectively collected breast care data reports on recurring 6-month and cumulative data from nine care locations from 2015 to 2021.
RESULTS
Breast care was provided to 6659 patients by 41 surgeons. A total of 27 breast care metrics were evaluated over 7 years. Metrics with consistent, proficient results were retired after 18 months, including the rate of core biopsy, specimen orientation, and referrals to medical oncology, genetics, and fertility, among others. In clinically node-negative, hormone receptor-positive patients 70 years of age or older, the cumulative rate of sentinel lymph node (SLN) biopsy significantly decreased by 40% over 5.5 years (p < .001). The overall breast conservation rate for T0-T2 cancer increased 10% over 7 years. At the surgeon level, improvements were made in the median number of SLNs removed and in operative note documentation.
CONCLUSIONS
Implementation of a surgeon-specific, peer comparison-based metric and tracking system has yielded substantive changes in breast care management. This process and governance structure can serve as a model for quantification of breast care at other institutions and for other disease sites.

Identifiants

pubmed: 37382238
doi: 10.1002/cncr.34924
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3230-3238

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

Références

United States Centers for Medicare and Medicaid Services. MACRA. Accessed September 26, 2022. https://www.cms.gov/medicare/quality-initiatives-patient-assessment-instruments/value-based-programs/macra-mips-and-apms/macra-mips-and-apms
United States Centers for Medicare and Medicaid Services. Quality Payment Program. Accessed September 26, 2022. https://qpp.cms.gov/mips/explore-measures?tab=qualityMeasures&py=2022#measures
Commission on Cancer. Optimal Resources for Cancer Care 2020 Standards; April 2022. Accessed August 15, 2022. https://www.facs.org/media/whmfnppx/2020_coc_standards.pdf
American College of Surgeons. National Accreditation Program For Breast Centers Standards Manual; 2018. Accessed August 15, 2022. https://www.facs.org/media/pofgxojm/napbc_standards_manual_2018.pdf
American College of Surgeons and the Commision on Cancer. Cancer Quality Improvement Program (CQIP). Accessed August 15, 2022. https://www.facs.org/media/0svjptqz/ncdb_tools_2021.pdf
Birkmeyer JD, Finks JF, O'Reilly A, et al. Surgical skill and complication rates after bariatric surgery. N Engl J Med. 2013;369(15):1434-1442. doi:10.1056/nejmsa1300625
Scally CP, Varban OA, Carlin AM, Birkmeyer JD, Dimick JB. Video ratings of surgical skill and late outcomes of bariatric surgery. JAMA Surg. 2016;151(6):e160428. doi:10.1001/jamasurg.2016.0428
Tam V, Zeh HJ, 3rd, Hogg ME. Incorporating metrics of surgical proficiency into credentialing and privileging pathways. JAMA Surg. 2017;152(5):494-495. doi:10.1001/jamasurg.2017.0025
Society of Surgical Oncology. Choosing Wisely. Don't routinely use sentinel node biopsy in clinically node negative women >70 years of age with early stage hormone receptor positive, HER2 negative invasive breast cancer; July 27, 2021. Accessed June 28, 2022. https://www.choosingwisely.org/clinician-lists/sso-sentinel-node-biopsy-in-node-negative-women-70-and-over/
Landercasper J, Attai D, Atisha D, et al. Toolbox to reduce lumpectomy reoperations and improve cosmetic outcome in breast cancer patients: The American Society of Breast Surgeons Consensus Conference. Ann Surg Oncol. 2015;22(10):3174-3183. doi:10.1245/s10434-015-4759-x
American College of Surgeons Cancer Research Program, Alliance for Clinical Trials in Oncology. Operative Standards for Cancer Surgery: Breast, Lung, Pancrease, Colon. Vol 1. Wolters Kluwer; 2015.
Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and breast cancer survival in the United States. JAMA Oncol. 2016;2(3):330-339. doi:10.1001/jamaoncol.2015.4508
Chung A, Gangi A, Amersi F, Zhang X, Giuliano A. Not performing a sentinel node biopsy for older patients with early-stage invasive breast cancer. JAMA Surg. 2015;150(7):683-684. doi:10.1001/jamasurg.2015.0647
American College of Surgeons. Cancer Surgery Standards Program. Accessed November 3, 2022. https://www.facs.org/quality-programs/cancer-programs/cancer-surgery-standards-program/
Liederbach E, Sisco M, Wang C, et al. Wait times for breast surgical operations, 2003-2011: a report from the National Cancer Data Base. Ann Surg Oncol. 2015;22(3):899-907. doi:10.1245/s10434-014-4086-7
American College of Surgeons. NCDB Announces New Breast Quality Measure. Accessed November 7, 2022. https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/cancer-programs-news/063022/ncdb-announces-new-breast-quality-measure/
Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881-888. doi:10.1016/s1470-2045(07)70278-4
Quan ML, Wells BJ, McCready D, Wright FC, Fraser N, Gagliardi AR. Beyond the false negative rate: development of quality indicators for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol. 2010;17(2):579-591. doi:10.1245/s10434-009-0658-3
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455-1461. doi:10.1001/jama.2013.278932
Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558-566. doi:10.1097/sla.0b013e3181b8fd5e
Zhao B, Tsai C, Hunt KK, Blair SL. Adherence to surgical and oncologic standards improves survival in breast cancer patients. J Surg Oncol. 2019;120:148-159. doi:10.1002/jso.25506
Tevis SE, James TA, Kuerer HM, et al. Patient-reported outcomes for breast cancer. Ann Surg Oncol. 2018;25(10):2839-2845. doi:10.1245/s10434-018-6616-1
Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: the BREAST-Q. Plast Reconstr Surg. 2009;124(2):345-353. doi:10.1097/prs.0b013e3181aee807
Liu LQ, Branford OA, Mehigan S. BREAST-Q measurement of the patient perspective in oncoplastic breast surgery: a systematic review. Plast Reconstr Surg Glob Open. 2018;6(8):e1904. doi:10.1097/gox.0000000000001904

Auteurs

Richard L White (RL)

Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

Michelle L Wallander (ML)

Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

Marjorie E Leighliter (ME)

Breast Clinic, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

Wei Sha (W)

Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

Pooja P Palmer (PP)

Division of Community and Social Impact, Atrium Health, Charlotte, North Carolina, USA.

Almira Sejdic (A)

Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

Jennifer H Benbow (JH)

Clinical Trials Office, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

Deba Sarma (D)

Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

Myra M Robinson (MM)

Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

Sally J Trufan (SJ)

Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

Terry Sarantou (T)

Division of Surgical Oncology, Department of Surgery, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH